ISPE LATAM 2026研讨会巴西版:连接拉丁美洲制药业的知识、社区与患者影响
ISPE LATAM 2026 Symposium – Brazil Edition: Knowledge, Community, and Patient Impact Across Latin America’s Pharmaceutical Industry
ISPE LATAM 2026研讨会巴西版汇聚阿根廷、巴西和墨西哥分会的负责人,围绕知识共享与社区建设展开交流。会议演讲涉及除菌过滤器验证、纯化水与注射用水系统的可持续性、PAT与在线TOC监测、隔离器系统设计及AI赋能运营等议题。
iSpeak Blog
13 November 2026
The ISPE LATAM 2026 Symposium—Brazil Edition created an opportunity to meet with leaders from ISPE’s Latin America Affiliates, the Argentina Affiliate, Brazil Affiliate, and Mexico Affiliate, and build relationships across the region. Dinner with these colleagues gave me time to hear about their work and strengthen connections. I was glad to spend time with Ana Lúcia Valente Dória, Martin Orcoyen, Maria Eugenia Carini, Alejandro Bustamante, Ricardo Miranda, Ana Kaneto, Jamila Delfraro, and Andre Goto. I am especially grateful for the time and effort these leaders invest in strengthening their Affiliates and creating opportunities for professionals across the region.
That spirit of connection continued through the symposium, where professionals shared experience and ideas across a wide range of topics. The program included far more presentations than I can cover here, so I chose a few to highlight. The value of a learning opportunity like this is the chance to hear how others approach current challenges, ask questions, and carry useful ideas back to daily work. That exchange reflects ISPE’s Knowledge pillar.
In my presentation, “Empowering Pharma Through Knowledge, Community, and Innovation,” I reflected on beginning my engineering career at Eli Lilly and Company nearly 40 years ago. My mentor, Bill Peterson, taught me that engineering is tested in practice and held high standards while investing in my development. His example helped shape my view that pharmaceutical manufacturing ultimately serves the quality of human life. I also encouraged everyone to think about the people who have been a “Bill Peterson” in their own lives, take time to thank those who helped them, and look for ways to become that kind of mentor to someone else. Questions afterward focused on where ISPE can help the industry move forward, including AI implementation, international cooperation, cell and gene therapy, and constructive engagement between industry and regulators. The exchange reinforced how much progress depends on sharing experience across organizations and disciplines.
Julio Velazquez focused on validating a sterilizing filter for the product and process in which it will actually be used. A nominal 0.22-micron rating and a passing integrity test do not, by themselves, demonstrate process-specific bacterial retention. Validation connects microbial-retention studies using a suitable challenge organism with integrity-test limits and representative worst-case process conditions. Formulation and operating parameters can affect filter performance. Compatibility questions such as adsorption and extractables or leachables also inform filter selection. The evidence must support the filter, configuration, and operating range as a system for that process.
Shlomo Sackstein connected sustainability to decisions across purified-water and water-for-injection systems. Rather than treating water generation as a stand-alone utility, he looked across generation, storage, distribution, and sanitation. Examples included membrane-based generation and ambient-temperature loops to reduce heat demand; ozone sanitation where appropriate; condensate recovery, variable-frequency pump drives, and reuse of reverse-osmosis reject. Each option has to be assessed against water quality, process needs, and system reliability. He emphasized that lasting water and energy savings depend on measuring results and involving staff in sustaining the changes.
Helena Rejala outlined pharmaceutical-water generation and where process analytical technology (PAT) and at-line total organic carbon can augment routine monitoring for conductivity, pH, and microbial quality. Her core implementation point was that PAT is a governed measurement system, not just an analyzer: it requires risk-based planning, qualified equipment, a validated method, comparison with existing test results, alert and action limits, data integrity, maintenance, and routine review. Automated data transfer, audit-trail review, and LIMS connections can support investigations and trend detection. The real value comes from recognizing trends earlier and using that information to make better operational decisions.
David Barbault’s presentation used a new facility design challenge to show how isolator decisions need to work as a connected system. The concept had to support sterile products including oncology treatments and ready-to-administer medicines, while maintaining Grade A conditions and appropriate containment. The design combined externally ducted, monitored process chambers with hydrogen peroxide bio-decontamination, automatic glove and enclosure leak testing, and validated airlocks and rapid-transfer ports with double-door connections for moving materials, product, and waste. Practical details mattered too: arranging baskets to expose surfaces, limiting hidden areas, and defining monitoring and testing in the customer’s contamination control strategy. Together, these choices showed that isolator performance depends on equipment, facility design, transfer practices, and procedures working in concert.
Maria Grahm addressed a persistent challenge for pharmaceutical companies: scientific and technological advances are moving faster than organizations can put them into practice. She described a connected life-sciences operating model linking research and development, critical environments, and production through digital threads, shared data, and AI-enabled operations. Rather than optimizing each area independently, the thread connects them so teams can focus on the area needing attention while improving the system as a whole. Her central point about AI was that it does not fail because of models; it fails when the structure around them is missing: connected data, processes, governance, and clear operational use.
The importance of accelerating innovation became personal through the story of a young man who recovered from aggressive cancer through precision medicine. His experience underscored what is at stake: getting safe, effective treatments to patients sooner. Connecting data and improving execution ultimately serve a practical purpose: helping life-sciences organizations deliver therapies to patients faster, reliably, safely, and at scale.
These conversations reflect what ISPE can make possible: learning from people who face similar challenges, building relationships across the industry, and turning shared knowledge into better outcomes for patients. If you work in the pharmaceutical industry in Latin America and are not yet an ISPE member, I invite you to explore membership and connect with the Affiliate community in your region. ISPE membership links you to local and regional events, training, mentoring, and networking, as well as global ISPE Communities of Practice and learning resources.
Connect with an ISPE Latin America Affiliate
About the Author
President and CEO
ISPE
Bringing a wealth of experience and expertise to this role, Mike has a distinguished career spanning more than 35 years in the pharmaceutical industry. Most...
References
来源:ISPE iSpeak 专家博客 · ispe.org